CA2908029C - Radiolabelling process - Google Patents

Radiolabelling process Download PDF

Info

Publication number
CA2908029C
CA2908029C CA2908029A CA2908029A CA2908029C CA 2908029 C CA2908029 C CA 2908029C CA 2908029 A CA2908029 A CA 2908029A CA 2908029 A CA2908029 A CA 2908029A CA 2908029 C CA2908029 C CA 2908029C
Authority
CA
Canada
Prior art keywords
formula
acid
compound
substituent
facbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2908029A
Other languages
English (en)
French (fr)
Other versions
CA2908029A1 (en
Inventor
Torild Wickstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CA2908029A1 publication Critical patent/CA2908029A1/en
Application granted granted Critical
Publication of CA2908029C publication Critical patent/CA2908029C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/15—Saturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2908029A 2013-03-28 2014-03-28 Radiolabelling process Active CA2908029C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1305687.4A GB201305687D0 (en) 2013-03-28 2013-03-28 Radiolabelling process
GB1305687.4 2013-03-28
PCT/EP2014/056344 WO2014154886A1 (en) 2013-03-28 2014-03-28 Radiolabelling process

Publications (2)

Publication Number Publication Date
CA2908029A1 CA2908029A1 (en) 2014-10-02
CA2908029C true CA2908029C (en) 2021-05-04

Family

ID=48444922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908029A Active CA2908029C (en) 2013-03-28 2014-03-28 Radiolabelling process

Country Status (12)

Country Link
US (2) US9999692B2 (en:Method)
EP (1) EP2978456B1 (en:Method)
JP (1) JP6500011B2 (en:Method)
KR (1) KR102218249B1 (en:Method)
CN (1) CN105120905B (en:Method)
AU (1) AU2014242897B2 (en:Method)
CA (1) CA2908029C (en:Method)
ES (1) ES2864702T3 (en:Method)
GB (1) GB201305687D0 (en:Method)
MX (1) MX368061B (en:Method)
RU (1) RU2675371C2 (en:Method)
WO (1) WO2014154886A1 (en:Method)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
US20220001034A1 (en) * 2014-06-30 2022-01-06 Ge Healthcare Limited Novel formulation and method of synthesis
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
WO2006126410A1 (ja) 2005-05-23 2006-11-30 Nihon Medi-Physics Co., Ltd. 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法
AU2006262425C1 (en) * 2005-06-23 2012-06-21 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
JP2009505947A (ja) 2005-06-23 2009-02-12 エモリー・ユニバーシティ 画像化剤
AU2007251015B2 (en) * 2006-05-11 2011-09-01 Nihon Medi-Physics Co., Ltd. Process for production of radioactive fluorine-labeled organic compound
AU2007335633A1 (en) 2006-12-21 2008-06-26 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
EP2119458B9 (en) * 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
RU2476423C2 (ru) 2007-12-19 2013-02-27 Нихон Меди-Физикс Ко., Лтд. Способ получения радиоактивного, меченного фтором органического соединения
SG182378A1 (en) 2009-10-08 2012-08-30 Ge Healthcare Ltd Purification method
EP2658831B1 (en) 2010-12-29 2017-02-15 GE Healthcare Limited Eluent solution
GB2509476B (en) * 2011-12-21 2018-08-08 Ge Healthcare Ltd Ip 18F - Fluciclovine compositions in citrate buffers
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process

Also Published As

Publication number Publication date
BR112015024344A2 (pt) 2017-07-18
RU2015138540A (ru) 2017-05-03
AU2014242897B2 (en) 2018-11-08
EP2978456A1 (en) 2016-02-03
US20160051710A1 (en) 2016-02-25
ES2864702T3 (es) 2021-10-14
US20180177900A1 (en) 2018-06-28
CA2908029A1 (en) 2014-10-02
JP2016515564A (ja) 2016-05-30
JP6500011B2 (ja) 2019-04-10
GB201305687D0 (en) 2013-05-15
CN105120905A (zh) 2015-12-02
MX2015013801A (es) 2016-02-16
US9999692B2 (en) 2018-06-19
KR102218249B1 (ko) 2021-02-22
RU2015138540A3 (en:Method) 2018-03-01
MX368061B (es) 2019-09-18
KR20150136598A (ko) 2015-12-07
CN105120905B (zh) 2021-07-06
AU2014242897A1 (en) 2015-08-27
EP2978456B1 (en) 2021-03-17
WO2014154886A1 (en) 2014-10-02
RU2675371C2 (ru) 2018-12-19

Similar Documents

Publication Publication Date Title
EP3766522B1 (en) Automated method for the preparation of 18f-fluciclovine compositions
US10023525B2 (en) Preparation of 18F-fluciclovine
CA2953641C (en) Novel formulation and method of synthesis
AU2014242897B2 (en) Radiolabelling process
EP2793954B1 (en) 18f-fluciclovine compositions in citrate buffers
GB2561122B (en) Composition comprising [18F]-Fluciclovine
BR112015024344B1 (pt) Método para obter uma composição
NZ624250A (en) 18f-fluciclovine compositions in citrate buffers
NZ624250B2 (en) 18f-fluciclovine compositions in citrate buffers
HK1197368A (en) 18f - fluciclovine compositions in citrate buffers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227